118 results about "Enzyme variant" patented technology

The present invention relates to detergent compositions comprising a detergent ingredient and a lipase variant with reduced potential for odor generation obtained by introducing mutations in one or more regions identified in a parent lipase.

The present invention relates to variants of a cell-wall degrading enzyme having a beta-helix structure, which variant has at least one substituent in a position determined by identifying all residues potentially belonging to a stack; characterizing the stack as interior or exterior; characterizing the stack as polar, hydrophobic or aromatic / heteroaromatic based on the dominating characteristics of the parent or wild-type enzyme stack residues and / or its orientation relative to the beta-helix (interior or exterior); optimizing all stack positions of a stack either to hydrophobic aliphatic amino acids, hydrophobic aromatic or polar amino acids by allowing mutations within one or all positions to amino acids belonging to one of these groups; measuring thermostability of the variants by DSC or an application-related assay such as a Pad-Steam application test; and selecting the stabilized variants. Variants of a wild-type parent pectate lyase (EC 4.2.2.2) having the conserved amino acid residues D111, D141 or E141, D145, K165, R194 and R199 when aligned with the pectate lyase comprising the amino acid sequence of SEQ ID NO: 2 are preferred.

An intronic, self-splicing riboswitch is configured for enzyme-product specificity by introducing an appropriate aptamer. This then provides a sensing-expression construct, whereby the presence of an enzyme product in the cell triggers self-splicing of the intron sequence to restore the reading frame of the reporter gene and as such to drive expression of the gene product. The sensing construct expresses a protein which marks the cell or permits its growth or survival in or on an otherwise selective media. In this way, introduction or the presence of such product sensing-reporter constructs in cells can be harnessed to provide a multi-parallel rapid screening of cells or libraries for desirable enzyme variants.

The present invention relates to newly identified asparaginase polypeptide variants of SEQ ID NO: 3 and to polynucleotide sequences that encode such novel asparaginase variants. Furthermore the invention relates to the use of these novel asparaginase variants in industrial processes.

The present invention provides methods of designing and generating polypeptide variants that have altered properties compared to a parent polypeptide. The present invention further provides a computer program product for carrying out the design of a variant polypeptide. The present invention further provides nucleic acids encoding enzyme variants, as well as vectors and host cells comprising the nucleic acids. The present invention further provides variant enzymes; methods of producing the variant enzymes; and methods of producing compounds using the enzymes.

The invention relates to a polypeptide having chymosin activity which: a. is capable of hydrolysing bovine alpha s1-casein at position F23F24 so as to form αs1-I CN (f24-199) more rapidly than camel chymosin; and b. has a C / P ratio higher than the C / P ratio of bovine chymosin.

The invention relates to recombinant expression of variant forms of C1 CBH1a and homologs thereof, having improved thermostability, low-pH tolerance, specific activity and other desirable properties. Also provided are methods for producing ethanol and other valuable organic compounds by combining cellobiohydrolase variants with cellulosic materials.

The present invention relates to pullulanase variants, wherein the variants have improved properties, for example, altered pH optimum, improved thermostability, altered substrate specificity, increased specific activity or altered cleavage pattern. The present invention also relates to methods of making pullulanase variants having at least one altered property based on the three-dimensional structure of a parent pullulanase.

An enzyme is described which enzyme is derived from family 13 of alpha-amylases. The enzyme variant is obtainable by modifying a CGTase or a maltogenic alpha-amylase. The enzyme is useful in preparing a food or a food product such as bakery products.

The present invention pertains to the use of engineered variants of enzyme CYP102A, also known as P450-BM3, for cyclopropanation of olefins containing electron-withdrawing groups. One exemplary enzyme variant, referred to as BM3-HStar, contains five mutations away from wild-type P450-BM3, and demonstrates high activity towards cyclopropanation of olefinic substrates using ethyldiazoacetate (EDA) and other carbene transfer reagents. Products of these reactions are potential precursors of levomilnacipran derivatives, a class of compounds that have been shown to be selective inhibitors of monoamine transporters. In addition, cyclopropanation reactions with the P450-BM3 enzyme variants of the invention can be conducted in whole cells expressing the enzyme variants and can proceed under aerobic conditions.

The invention discloses a cephalosporin acylase mutant and an encoding gene and an application thereof. The protein provided by the invention is any one of the following 1)-3): 1) protein formed by an amino acid sequence shown as sequence 4 in the sequence table; 2) protein formed by an amino acid sequence shown as sequence 3 in the sequence table; 3) protein which is obtained by substitution and / or deletion and / or addition of one or several amino acid residues in the amino acid residue sequence of sequence 3 or sequence 4 in the sequence table, has the functions of cephalosporin acylase, andis derived from 1). Experiment of the invention shows that the invention provides a wild-type CPC acylase mutant; HPLC results show that the specific activity for CPC of the wild-type CPC acylase mutant of the invention is increased by 6.5 times when compared with that of wild-type enzymes. In one-step conversion, the conversion rate is up to above 98% within 3 hours.

A novel modified polypeptide having an isopropylmalate synthase activity, a polynucleotide encoding the same, a microorganism comprising the polypeptide, and a method of producing L-leucine by culturing the microorganism.

The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.

The present invention relates to alkaline cellulase variants having an amino acid sequence which exhibits at least 95% homology with the amino acid sequence of SEQ ID NO: 2, wherein said alkaline cellulase variant is mutated to include at least one substitution at (a) position 10, (b) position 16, (c) position 22, (d) position 33, (e) position 39, (f) position 76, (g) position 109, (h) position 242, (i) position 263, (j) position 308, (k) position 462, (l) position 466, (m) position 468, (n) position 552, (o) position 564, or (p) position 608 in SEQ ID NO: 2, or at a position corresponding thereto, wherein said alkaline cellulase variant has alkaline cellulase activity. The present invention also relates to a gene encoding the variant; a vector containing the gene; a transformant containing the vector; and a detergent composition containing the alkaline cellulase variant.

The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.

The present invention relates to detergent compositions comprising lipase variants. The present invention also relates to lipase variants and polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

A number of human beta-glucuronidase variants having higher enzymatic activity at physiological pH as compared with wild-type beta-glucuronidase and uses thereof in prodrug therapy. Also disclosed herein is a method for identifying enzyme variants having elevated enzymatic activity using a mammalian surface display system.

The present disclosure relates to novel glycosynthase enzymes for glycoprotein engineering and / or homogeneous antibody remodeling. The enzyme variants, termed EndoSd-D232M and EndoSz-D234M, contain the glycan conjugation and / or modification activity at the conserved N297 glycosylation site of Fc region of an exemplary antibody. It has been demonstrated that the glycosynthase activities of EndoSd-D232M and EndoSz-D234M can be applied to various mAbs targeting different receptors, including, but not limited to, Globo H, SSEA-4, SSEA-3 series of receptors (OBI-888; Globo H ganglioside), Herceptin (Her 2 receptor), Perjeta (Her 2 receptor) and Vectibix (EGFR receptor). It has been found that both mAb-GlcNAc and mAb-GlucNAc(F) were suitable substrates for both EndoSd-D232M and EndoSz-D234M. The ADCC assay of related products, OBI-888-G2S2 and Herceptin-G2S2, showed that the remodeled homogeneous antibody, mAb-G2S2, has an increased relative activity ranging from 3 to 26 folds.

The present invention relates to lipase variants and methods of obtaining them. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

The present invention relates to detergent compositions comprising a detergent ingredient and a lipase variant with reduced potential for odor generation obtained by introducing mutations in one or more regions identified in a parent lipase.

The invention provides variant lipases, preferably, variants with reduced tendency to odor generation obtained by introducing mutations in one or more regions identified in a parent lipase.

A variety of T4DNA ligase mutants that exhibit enhanced ligation activity at high salt concentrations as compared to wild-type ligases are engineered, characterized and selected via gel electrophoresis of ligation products from standard ligation assays. A ligase catalyzes the formation of a phosphodiester bond between the 5'end and the 3 'end of complementary cohesive or blunt ends of double helix DNA, which process is crucial for many molecular biological processes, including cloning and sequencing.

A number of human beta-glucuronidase variants having higher enzymatic activity at physiological pH as compared with wild-type beta-glucuronidase and uses thereof in prodrug therapy. Also disclosed herein is a method for identifying enzyme variants having elevated enzymatic activity using a mammalian surface display system.

The invention relates to a 1, 3-propanediol oxidoreductase isozyme mutated gene and application thereof. By utilizing error-prone PCR technique-mediated random mutation, the1, 3-propanediol oxidoreductase isozyme mutated gene is obtained by screening. The codon GAC of the No. 99 aspartic acid in the gene is mutated as the codon CAA of glutamine; the codon AAC of the No. 147 asparaginate is mutated as histidine CAC; a nucleotide sequence of the mutated gene is SEQ ID No.1, and is capable of being encoded as 1, 3-propanediol oxidoreductase mutated isozyme. The invention creates 1, 3-propanedioloxidoreductase mutated isozyme that has relatively high catalytic activity to 3-Hydroxypropionaldehyde and can catalyze the 3-hydroxypropionaldehyde to produce chemical raw material 1, 3-propanediol.Compared with the 1, 3-propanediol reducase isozyme, the activity of one of the tested cases is increased by 4 to 4.6 times, which provides broad application prospect for bio-transformed production chemical material 1, 3-propanediol.

Human cystathionine β-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine β-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologues are described. In addition, a method to express and purify recombinant human cystathionine β-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described.

The present invention provides methods of designing and generating polypeptide variants that have altered properties compared to a parent polypeptide. The present invention further provides a computer program product for carrying out the design of a variant polypeptide. The present invention further provides nucleic acids encoding enzyme variants, as well as vectors and host cells comprising the nucleic acids. The present invention further provides variant enzymes; methods of producing the variant enzymes; and methods of producing compounds using the enzymes.

The present invention provides methods for engineering proteins to optimize their performance under certain environmental conditions of interest. In some embodiments, the present invention provides methods for engineering enzymes to optimize their catalytic activity under particular environmental conditions. In some preferred embodiments, the present invention provides methods for engineering enzymes to optimize their catalytic activity and / or stability under adverse environmental conditions. In some preferred embodiments, the present invention provides methods for engineering enzymes to optimize their storage stability, particularly under adverse environmental conditions. In some preferred embodiments, the present invention provides methods for altering the net surface charge and / or surface charge distribution of enzymes (e.g., metalloproteases) to obtain enzyme variants that demonstrate improved performance and / or stability in detergent formulations as compared to the starting or parent enzyme.

The present invention related to lipase variants having lipase activity and having between 60% to less than 100% sequence identity to a parent lipase or a fragment thereof, wherein the variant comprises one or more substitutions selected from H198A / D / E / F / G / I / L / N / Q / S / T / V / Y, F7H / K / R, F51A / I / L / V / Y, T143A / G / S / V, A150G / V, N200H / K / Q / R, I202G / L / V, S224C / F / H / I / L / P / Y, L227D / E / K / R, V228P, P229H / K / R, V230H / K / L / R, I255A / G / N / P / S / T / V / Y, P256A / K / N / Q / R / S / T / W, A257F / H / I / L / V / Y, L259F / Y, and W260D / E / F / H / I / L / N / Q / S / T / Y using SEQ ID NO:10 for position numbering or selected from H198A / D / E / F / G / I / L / N / Q / S / T / V / Y, F7H / K / R, F51A / I / L / V / Y, T143A / G / S / V, A150G / V, N200H / K / Q / R, I202G / L / V, S224C / F / H / I / L / P / Y, L227D / E / K / R, V228P, P229H / K / R, V230H / K / L / R, I255A / G / N / P / S / T / V / Y, T256A / K / N / Q / R / S / P / W, A257F / H / I / L / V / Y, L259F / Y, and W260D / E / F / H / I / L / N / Q / S / T / Y using SEQ ID NO:2 for position numbering. Further the invention relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; to compositions comprising the variants as well as methods of producing and using the variants.

The present invention relates to cellobiohydrolase variants having improved thermostability in comparison to wild-type CBH2a.

The invention relates to a genetically engineered variant of a parent starch debranching enzyme, i.e. a pullulanase or an isamylase, the enzyme variant having an improved thermostability at a pH in the range of 4-6 compared to the parent enzyme and / or an increased activity towards amylopectin and / or glycogen compared to the parent enzyme, to methods for producing such starch debranching enzyme variants with improved thermostability and / or altered substrate specificity, and to a method for converting starch to one or more sugars using at least one such enzyme variant.